Intimate Partner Violence and the HIV Care and Treatment Cascade Among Adolescent Girls and Young Women in DREAMS, South Africa

• Published in: Journal of acquired immune deficiency syndromes (1999) Vol. 89; no. 2; pp. 136 - 142
• Main Authors: Gibbs, Andrew, Reddy, Tarylee, Closson, Kalysha, Cawood, Cherie, Khanyile, David, Hatcher, Abigail
• Format: Journal Article
• Language: English
• Published: United States JAIDS Journal of Acquired Immune Deficiency Syndromes 01-02-2022; Lippincott Williams & Wilkins Ovid Technologies
• Subjects: Adolescent; Adolescents; Aggression; Antiretroviral agents; Antiretroviral therapy; Benchmarks; Blood; Cross-Sectional Studies; Domestic violence; Epidemiology; Female; Girls; HIV; HIV Infections - drug therapy; HIV Infections - epidemiology; Human immunodeficiency virus; Humans; Intimate Partner Violence; Prevalence; Risk Factors; Secondary analysis; Sexual Partners; Sexually transmitted diseases; South Africa - epidemiology; STD; Violence; Women; South Africa
• ISSN: 1525-4135; 1944-7884
• DOI: 10.1097/QAI.0000000000002843

Intimate partner violence (IPV) may affect the HIV-treatment cascade.
Four high HIV-prevalence DREAMS health districts in South Africa.
Secondary analysis of cross-sectional data collected March 2017-June 2018, using random household sample of young (12-24 years) girls and women. Face-to-face interviews assessed IPV and HIV-status knowledge, and finger-prick blood draws assessed ART (antiretroviral therapy) uptake and viral suppression. We used logistic regression to estimate crude and adjusted effects of IPV on HIV knowledge, ART uptake, and viral suppression.
Of 18,230 adolescent girls and young women, 8413 (46%) reported ever having had sex, of whom 1118 (13%) were HIV positive. The 90:90:90 benchmarks were 61% knew their status, 86% had ART present in their blood sample, and 91% were virally suppressed. Among the entire sample of young women living with HIV, 65.6% were virally suppressed. Past year IPV was reported by 15%. In adjusted models, IPV trended toward increasing the odds that a young woman was aware she was living with HIV [adjusted odds ratios (aOR) = 1.40, 2.00-9.98, P = 0.067]. There was no association between IPV and reduced treatment use (aOR = 0.73, 0.41-1.29). IPV was independently associated with reduced viral suppression (aOR = 0.30, 0.13-0.66).
Addressing the role of IPV in undermining the treatment cascade for adolescent and young women is a critical issue for HIV programming.